Cipla's Revenue Growth Defies Market Challenges Despite Profit Drop
Cipla Ltd reported a 55.32% drop in net profit due to challenges in North American markets and high expenses. Despite this, the company achieved its highest-ever yearly revenue, driven by strong growth in India. Cipla plans to focus on expanding key markets and resolving regulatory issues.
Cipla Ltd, a leading drugmaker, reported a significant drop in net profit for the March quarter, plummeting by 55.32% to Rs 542.51 crore due to slumping revenues in North America and increased expenditures.
The company has, however, achieved its highest-ever annual revenue, indicative of a resilient core business. Notably, its 'One India' sales increased by 15% compared to the same period last year, highlighting Cipla's robust domestic market strategy.
Despite challenges, Cipla plans to grow key markets, enhance flagship brands, and prioritize regulatory resolutions. The board recommended a final dividend for shareholders, showcasing confidence in its ongoing financial strategy.
ALSO READ
-
Foxconn Cyberattack: North American Facilities Targeted, Data Breach Confirmed
-
Dr Reddy's Labs Faces Profit Decline Amidst North American Challenges
-
IHCL's Impressive Financial Performance: A 14.71% Surge in Q4 Net Profit
-
Exim Bank FY26 net profit jumps 32 pc to Rs 4,273 cr
-
ABB India net profit falls 25 pc to Rs 342 cr in Mar qtr
Google News